Drug firms say they'll take closer look at the docs they pay
Several of the nation's largest pharmaceutical companies said they plan to tighten screening of physicians who promote their drugs after ProPublica reported last month that more than 250 of them had been sanctioned for misconduct.
Eli Lilly and Co. said that next year, for the first time, it would hire an outside firm to search for state disciplinary actions against its hired speakers and advisers. Lilly, the seventh-largest company by U.S. prescription sales, did not previously conduct such screening and was unaware of the dozens of actions ProPublica found against its speakers.
"Your reporting has raised valid and important questions, which we have taken steps to address," spokesman J. Scott MacGregor said in a statement.
- CMS to Speak with ICD-10 Backers Tuesday
- Feds Stonewall ICD-10 Summit
- Boston Marathon Bombing Yields Lessons for Hospitals
- Governor Details Healthcare Payment Reform Path in Arkansas
- Hospital Groups Back NQF Report on Patient Sociodemographics
- Managed Care Contract Negotiations Morph Under PPACA
- Cyberattack Drill Exposes Healthcare's Vulnerabilities
- Physician Payment Data is Where the Action Is
- NY Abolishes Written Practice Agreement for NPs
- MetroHealth Revs Its Population Health Engine